Key Points
- Director Glenn Md Phd Steele, Jr. sold 12,000 shares on Jan. 2 at an average $76.35 for $916,200, cutting his holding by 39.34% to 18,500 shares valued at about $1.41M.
- PTC reported a strong quarter with $0.20 EPS (vs. -$1.19 est.) and $211.0M revenue (vs. $177.4M est.), though analysts still project a FY loss (consensus -4.52 EPS).
- The stock trades near $76.70 with a $6.16B market cap and a 52‑week range of $35.95–$87.50; analyst coverage is mixed with an average rating of "Hold" and an average target of $76.00.
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Emma Reeve sold 734 shares of the firm's stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $76.00, for a total value of $55,784.00. Following the completion of the sale, the director owned 10,666 shares of the company's stock, valued at approximately $810,616. This represents a 6.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Emma Reeve also recently made the following trade(s):
- On Wednesday, December 3rd, Emma Reeve sold 733 shares of PTC Therapeutics stock. The stock was sold at an average price of $78.62, for a total value of $57,628.46.
- On Friday, November 21st, Emma Reeve sold 10,000 shares of PTC Therapeutics stock. The stock was sold at an average price of $79.50, for a total value of $795,000.00.
- On Wednesday, November 12th, Emma Reeve sold 7,333 shares of PTC Therapeutics stock. The shares were sold at an average price of $74.50, for a total value of $546,308.50.
- On Thursday, October 30th, Emma Reeve sold 15,666 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.50, for a total value of $1,088,787.00.
PTC Therapeutics Stock Down 0.1%
Shares of PTCT opened at $76.70 on Wednesday. The business's fifty day moving average is $76.06 and its 200 day moving average is $62.32. PTC Therapeutics, Inc. has a 12-month low of $35.95 and a 12-month high of $87.50. The stock has a market cap of $6.16 billion, a P/E ratio of 8.96 and a beta of 0.49.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of ($1.19) by $1.39. The firm had revenue of $211.01 million for the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The business's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the firm earned ($1.39) earnings per share. On average, analysts expect that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.
Institutional Investors Weigh In On PTC Therapeutics
A number of hedge funds have recently made changes to their positions in the business. AlphaQuest LLC raised its position in PTC Therapeutics by 337.7% in the second quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company's stock worth $386,000 after acquiring an additional 6,102 shares during the period. Vise Technologies Inc. purchased a new stake in shares of PTC Therapeutics during the 2nd quarter worth approximately $486,000. Prudential Financial Inc. raised its holdings in shares of PTC Therapeutics by 35.5% in the 2nd quarter. Prudential Financial Inc. now owns 84,250 shares of the biopharmaceutical company's stock worth $4,115,000 after purchasing an additional 22,060 shares during the period. Hussman Strategic Advisors Inc. raised its holdings in shares of PTC Therapeutics by 200.0% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 63,000 shares of the biopharmaceutical company's stock worth $3,077,000 after purchasing an additional 42,000 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in PTC Therapeutics by 241.4% in the second quarter. Acadian Asset Management LLC now owns 127,793 shares of the biopharmaceutical company's stock valued at $6,234,000 after purchasing an additional 90,358 shares during the last quarter.
Wall Street Analysts Forecast Growth
A number of analysts have commented on PTCT shares. The Goldman Sachs Group boosted their price objective on PTC Therapeutics from $44.00 to $50.00 and gave the stock a "sell" rating in a report on Wednesday, November 5th. Jefferies Financial Group lifted their target price on PTC Therapeutics from $63.00 to $77.00 and gave the company a "buy" rating in a research report on Tuesday, October 28th. Wells Fargo & Company increased their price target on PTC Therapeutics from $73.00 to $93.00 and gave the company an "overweight" rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of PTC Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, TD Cowen increased their target price on shares of PTC Therapeutics from $50.00 to $63.00 and gave the company a "hold" rating in a report on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $76.00.
View Our Latest Analysis on PTCT
About PTC Therapeutics
(
Get Free Report)
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
